Resveratrol in cancer: Cellular and mitochondrial consequences of proton transport inhibition

Current Pharmaceutical Design

Volumn 18, Issue 10, 2012, Pages 1338-1344

  López Lluch, Guillermo ^a   Cruz Calvo, Sara Santa ^a   Navas, Plácido ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Angiogenesis; Cell growth; Mitochondria; Polyphenols; Resveratrol

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ANTIMYCIN A1; BAFILOMYCIN A1; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; POLYPHENOL; PROTON PUMP INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RESVERATROL; STIGMATELIN; STILBENE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL MEMBRANE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLYCOLYSIS; METABOLISM; MITOCHONDRION; NEOPLASM; PRIORITY JOURNAL; TISSUE METABOLISM; TUMOR CELL;

EID: 84857772567     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799504849     Document Type: Article

References (76)

1. Annibaldi A, Widmann C. Glucose metabolism in cancer cells. Curr Op Clin Nutr Metab Care 2010; 13:466-470.
2. Sanchez-Arago M, Chamorro M, Cuezva JM. Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis 2010; 31:567-576.
3. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Moreno-Sanchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 2010; 31:29-59.
4. [] Warburg O. On the origin of cancer cells. Science 1956; 123:309- 314.
5. Cuezva JM, Krajewska M, de Heredia ML, et al. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 2002; 62:6674-6681.
6. Isidoro A, Martinez M, Fernandez PL, et al. Alteration of the bio- energetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer. Biochem J 2004; 378:17-20.
7. Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Bioche Biophys Res Commun 2004; 313:459-65.
8. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444:337-342.
9. López-Lluch G, Siendones E, Fernández-Ayala DJM, Navas P. Antioxidants in differentiation of leukemic cells. In: Saitama H, Ed. New cell differentiation research topics: Hauppauge NY, Nova Science Publishers, Inc, 2008; pp. 79-116.
10. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008; 7:1020-1035.
11. [] Aiyar SE, Park H, Aldo PB, et al. TMS, a chemically modified herbal derivative of Resveratrol, induces cell death by targeting Bax. Breast Cancer Res Treat 2010; 124:265-277.
12. Wu JY, Tsai KW, Shee JJ, et al. 4'-Chloro-3,5-dihydroxystilbene, a resveratrol derivative, induces lung cancer cell death. Acta Pharmacol Sin 2010; 31:81-92.
13. Guo L, Peng Y, Yao J, Sui L, Gu A, Wang J. Anticancer activity and molecular mechanism of resveratrol-bovine serum albumin nanoparticles on subcutaneously implanted human primary ovarian carcinoma cells in nude mice. Cancer Biother Radiopharm 2010; 25:471-477.
14. Sun W, Wang W, Kim J, et al. Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv Exper Med Biol 2008; 614:179-186.
15. Gogada R, Prabhu V, Amadori M, Scott R, Hashmi S, Chandra D. Resveratrol Induces p53-Independent, XIAP-Mediated Bax Oli-gomerization on Mitochondria to Initiate Cytochrome c Release and Caspase Activation. J Biol Chem 2011; 286:28749-28760.
16. Alosi JA, McDonald DE, Schneider JS, Privette AR, McFadden DW. Pterostilbene inhibits breast cancer in vitro through mito-chondrial depolarization and induction of caspase-dependent apop-tosis. J Surg Res 2010; 161:195-201.
17. Martinez-Outschoorn UE, Pestell RG, Howell A, et al. Energy transfer in parasitic cancer metabolism: Mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell cycle 2011; 10: 4065-4073.
18. Zini R, Morin C, Bertelli A, Bertelli AA, Tillement JP. Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res 1999; 25:87-97.
19. Khutornenko AA, Roudko VV, Chernyak BV, Vartapetian AB, Chumakov PM, Evstafieva AG. Pyrimidine biosynthesis links mi-tochondrial respiration to the p53 pathway. Proc Natl Acad Sci USA 2010; 107:12828-12833.
20. Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ. Res-veratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Annals NY Acad Sci 2007; 1095:441-448.
21. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 2004; 101:3329-3335.
22. Guan TJ, Qin FJ, Du JH, Geng L, Zhang YY, Li M. AICAR inhibits proliferation and induced S-phase arrest, and promotes apoptosis in CaSki cells. Acta pharmacologica Sinica 2007; 28:1984-1990.
23. Willers IM, Cuezva JM. Post-transcriptional regulation of the mito-chondrial H(+)-ATP synthase: a key regulator of the metabolic phenotype in cancer. Biochim Biophys Acta 2011; 1807:543-551.
24. Isidoro A, Casado E, Redondo A, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis 2005; 26:2095-2104.
25. Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res 2007; 67:9013-9017.
26. Ortega AD, Sala S, Espinosa E, Gonzalez-Baron M, Cuezva JM. HuR and the bioenergetic signature of breast cancer: a low tumor expression of the RNA-binding protein predicts a higher risk of disease recurrence. Carcinogenesis 2008; 29:2053-2061.
27. de Heredia ML, Izquierdo JM, Cuezva JM. A conserved mechanism for controlling the translation of beta-F1-ATPase mRNA between the fetal liver and cancer cells. J Biol Chem 2000; 275: 7430-7437.
28. Santamaria G, Martinez-Diez M, Fabregat I, Cuezva JM. Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase. Carcinogenesis 2006; 27:925-935.
29. Kunze B, Sasse F, Wieczorek H, Huss M. Cruentaren A, a highly cytotoxic benzolactone from Myxobacteria is a novel selective inhibitor of mitochondrial F1-ATPases. FEBS Lett 2007; 581: 3523-3527.
30. Sanchez-Cenizo L, Formentini L, Aldea M, et al. Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H+-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. J Biol Chem 2010; 285:25308-25313.
31. Zheng J, Ramirez VD. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. Brit J Pharmacol 2000; 130:1115-1123.
32. Dadi PK, Ahmad M, Ahmad Z. Inhibition of ATPase activity of Escherichia coli ATP synthase by polyphenols. Int J Biol Macro-mol 2009; 45:72-79.
33. Ahmad Z, Laughlin TF. Medicinal chemistry of ATP synthase: a potential drug target of dietary polyphenols and amphibian antimicrobial peptides. Current Med Chem 2010; 17:2822-2836.
34. Murakami S, Arai I, Muramatsu M, et al. Inhibition of gastric H+,K(+)-ATPase and acid secretion by cassigarol A, a polyphenol from Cassia garrettiana Craib. Bioch Pharmacol 1992; 44:33-37.
35. Zheng J, Ramirez VD. Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem Biophys Res Commun 1999; 261:499-503.
36. Gledhill JR, Walker JE. Inhibition sites in F1-ATPase from bovine heart mitochondria. Biochem J 2005; 386:591-598.
37. Gledhill JR, Montgomery MG, Leslie AG, Walker JE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related poly-phenols. Proc Natl Acad Sci USA 2007; 104:13632-13637.
38. Kipp JL, Ramirez VD. Effect of estradiol, diethylstilbestrol, and resveratrol on F0F1-ATPase activity from mitochondrial preparations of rat heart, liver, and brain. Endocrine 2001; 15:165-175.
39. Bjorklund M, Roos J, Gogvadze V, Shoshan M. Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment. Cancer Chemother Pharmacol 2011.
40. Arakaki N, Nagao T, Niki R, et al. Possible role of cell surface H+ -ATP synthase in the extracellular ATP synthesis and proliferation of human umbilical vein endothelial cells. Mol Cancer Res 2003; 1:931-939.
41. Burwick NR, Wahl ML, Fang J, et al. An Inhibitor of the F1 subunit of ATP synthase (IF1) modulates the activity of angiostatin on the endothelial cell surface. J Biol Chemistry 2005; 280:1740-1745.
42. Das B, Mondragon MO, Sadeghian M, Hatcher VB, Norin AJ. A novel ligand in lymphocyte-mediated cytotoxicity: expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines. J Exper Med 1994; 180:273-281.
43. Mangiullo R, Gnoni A, Leone A, Gnoni GV, Papa S, Zanotti F. Structural and functional characterization of F(0)F(1)-ATP syn-thase on the extracellular surface of rat hepatocytes. Biochim Bio-phys Acta 2008; 1777:1326-1335.
44. Yamamoto K, Shimizu N, Obi S, et al. Involvement of cell surface ATP synthase in flow-induced ATP release by vascular endothelial cells. Am J Physiol 2007; 293:H1646-H1653.
45. Martinez LO, Jacquet S, Esteve JP, et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL en-docytosis. Nature 2003; 421:75-79.
46. Cortes-Hernandez P, Dominguez-Ramirez L, Estrada-Bernal A, et al. The inhibitor protein of the F1F0-ATP synthase is associated to the external surface of endothelial cells. Biochem Biophys Res Commun 2005; 330:844-849.
47. Huang TC, Chang HY, Hsu CH, Kuo WH, Chang KJ, Juan HF. Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J Proteom Res 2008; 7:1433-1444.
48. Ravera S, Aluigi MG, Calzia D, Ramoino P, Morelli A, Panfoli I. Evidence for Ectopic Aerobic ATP Production on C6 Glioma Cell Plasma Membrane. Cel Mol Neurobiol 2011; 31:313-321.
49. Hu Y, Sun CY, Huang J, Hong L, Zhang L, Chu ZB. Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J 2007; 120:1672-7.
50. Lee EO, Lee HJ, Hwang HS, et al. Potent inhibition of Lewis lung cancer growth by heyneanol A from the roots of Vitis amurensis through apoptotic and anti-angiogenic activities. Carcinogenesis 2006; 27:2059-2069.
51. Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endo-thelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyro-sine phosphorylation. Mol Pharmacol 2003; 64:1029-1036.
52. Kunimasa K, Ohta T, Tani H, et al. Resveratrol derivative-rich melinjo (Gnetum gnemon L.) seed extract suppresses multiple an-giogenesis-related endothelial cell functions and tumor angiogene-sis. Mol Nut Food Res 2011 55:1730-174.
53. Alex D, Leong EC, Zhang ZJ, et al. Resveratrol derivative, trans-3,5,4'-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation. J Cel Biochem 2010; 109:339-346.
54. El-Azab M, Hishe H, Moustafa Y, El-Awady el S. Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice. Eur J Pharmacol 2011; 652:7-14.
55. Shamim U, Hanif S, Albanyan A, et al. Resveratrol-induced apop-tosis is enhanced in low pH environments associated with cancer. J Cel Physiol 2011; in press DOI: 10.1002/jcp.22865.
56. De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Fut Oncol 2005; 1:779-786.
57. Lim JH, Park JW, Kim MS, Park SK, Johnson RS, Chun YS. Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing hypoxia-inducible factor-1alpha. Mol Pharmacol 2006; 70:1856-1865.
58. Nishisho T, Hata K, Nakanishi M, et al. The a3 isoform vacuolar type H-ATPase promotes distant metastasis in the mouse B16 melanoma cells. Mol Cancer Res 2011; 9:845-855.
59. Lu X, Qin W, Li J, et al. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 2005; 65:6843-6849.
60. Thews O, Nowak M, Sauvant C, Gekle M. Hypoxia-induced extracellular acidosis increases p-glycoprotein activity and chemore-sistance in tumors in vivo via p38 signaling pathway. Adv Exper Med Biol 2011; 701:115-122.
61. Sauvant C, Nowak M, Wirth C, et al. Acidosis induces multi-drug resistance in rat prostate cancer cells (AT1) in vitro and in vivo by increasing the activity of the p-glycoprotein via activation of p38. Int J Cancer 2008; 123:2532-2542.
62. Smallbone K, Gatenby RA, Gillies RJ, Maini PK, Gavaghan DJ. Metabolic changes during carcinogenesis: potential impact on inva-siveness. J Theor Biol 2007; 244:703-713.
63. Pena-Llopis S, Vega-Rubin-de-Celis S, Schwartz JC, et al. Regulation of TFEB and V-ATPases by mTORC1. EMBO J 2011; 30:3242-3258.
64. Seeliger H, Guba M, Kleespies A, Jauch KW, Bruns CJ. Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Met Rev 2007; 26:611-621.
65. Zha X, Sun Q, Zhang H. mTOR upregulation of glycolytic enzymes promotes tumor development. Cell cycle 2011; 10:1015-1016.
66. Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anti-cancer Agents Med Chem 2010; 10:571-581.
67. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PloS One 2008; 3:e2599.
68. Ledur PF, Villodre ES, Paulus R, Cruz LA, Flores DG, Lenz G. Extracellular ATP reduces tumor sphere growth and cancer stem cell population in glioblastoma cells. Purinergic Signal 2011, in press.
69. [Bird MM, Lopez-Lluch G, Ridley AJ, Segal AW. Effects of microinjected small GTPases on the actin cytoskeleton of human neutrophils. J Anat 2003; 203:379-389.
70. Yaguchi T, Saito M, Yasuda Y, Kanno T, Nakano T, Nishizaki T. Higher concentrations of extracellular ATP suppress proliferation of Caco-2 human colonic cancer cells via an unknown receptor involving PKC inhibition. Cell Physiol Biochem 2010; 26:125-134.
71. Shabbir M, Thompson C, Jarmulowiczc M, Mikhailidis D, Burn-stock G. Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. BJU international 2008; 102:108-112.
72. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochim Biophys Acta 2011; 1808:1400-1412.
73. White N, Burnstock G. P2 receptors and cancer. Trends Pharmacol Sci 2006; 27:211-7.
74. Yegutkin GG, Marttila-Ichihara F, Karikoski M, et al. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 2011; 41:1231-1241.
75. Feng L, Sun X, Csizmadia E, et al. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia 2011; 13:206-16.
76. Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta 2008; 1783:673-94.